0000899243-18-018332.txt : 20180627
0000899243-18-018332.hdr.sgml : 20180627
20180627163030
ACCESSION NUMBER: 0000899243-18-018332
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180625
FILED AS OF DATE: 20180627
DATE AS OF CHANGE: 20180627
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ZDRAVESKI ZORAN
CENTRAL INDEX KEY: 0001741285
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38541
FILM NUMBER: 18922093
MAIL ADDRESS:
STREET 1: C/O MAGENTA THERAPEUTICS
STREET 2: 50 HAMPSHIRE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Magenta Therapeutics, Inc.
CENTRAL INDEX KEY: 0001690585
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 FIRST STREET
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 857-201-2700
MAIL ADDRESS:
STREET 1: 245 FIRST STREET
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-25
0
0001690585
Magenta Therapeutics, Inc.
MGTA
0001741285
ZDRAVESKI ZORAN
C/O MAGENTA THERAPEUTICS, INC.
50 HAMPSHIRE STREET
CAMBRIDGE
MA
02139
0
1
0
0
See Remarks
Common Stock
2018-06-25
4
C
0
4643
A
140092
D
Series C Preferred Stock
2018-06-25
4
C
0
12000
D
Common Stock
4643
0
D
The Series C Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Series C Preferred Stock had no expiration date.
Secretary and Chief Legal Officer
/s/Zoran Zdraveski
2018-06-27